Impel

Impel NeuroPharma is a medical device company that has developed a novel drug delivery device, dedicated to creating life-changing innovative therapies for central nervous system (CNS) diseases. Impel's products are based on a new intranasal delivery platform, POD™, which delivers medication to the upper nasal cavity in a consistent and predictable manner. The company is currently researching INP104 (POD™) for acute migraine, INP103 (POD™ Levodopa) for the treatment of Parkinson’s disease, INP105 (POD™ Olanzapine) for agitation in patients with schizophrenia and bipolar disorder, and INP102 (POD™ Insulin) for the treatment of Alzheimer’s disease.Impel is also a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients with highly unmet medical needs, initially concentrating on CNS or central nervous system diseases. Our company was founded on the premise that the upper nasal cavity can serve as an optimal therapeutic entry point for CNS and other diseases where rapid vascular absorption can lead to superior clinical outcomes.